Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Integrative Study of a High-Grade B-Cell Lymphoma Cohort of 45 Patients: A Single Institution Real Life Study

Louise Roulin, Elsa Poullot, Paul Blanc-Durand, Cyrielle Robe, Francois Lemonnier, Fabien Le Bras, Romain Gounot, Karim Belhadj, Jehan Dupuis, Mohammad Hammoud, Taoufik El Gnaoui, Sebastien Mule, Christiane Copie Bergman, Thierry Molina, Marie Helene Delfau Larue, Emmanuel Itti, Philippe Gaulard, Corinne Haioun

Blood (2021) 138 (Supplement 1): 4576.

https://doi.org/10.1182/blood-2021-152627

Published: 2021

Journal Articles

Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. a Real Life Study in Patients Ineligible for Autologous Transplantation

Clarisse Cazelles, Karim Belhadj, Helene Vellemans, Vincent Camus, Christiane Copie, MD PhD, Liana Veresezan, MD, Emmanuel Itti, MD PhD, Stephanie Becker, MD, Muriel verlinde Carvalho, Jehan Dupuis, MD, Fabien Le Bras, Francois Lemonnier, MD PhD, Louise Roulin, MD, Taoufik El Gnaoui, Fabrice Jardin, Nicolas Mounier, MD, Herve Tilly, MD PhD, Corinne Haioun, MD PhD

Blood (2019) 134 (Supplement_1): 4115.

https://doi.org/10.1182/blood-2019-124143

Published: 2019

Journal Articles

Clinical, Immunophenotypic and Genetic Characteristics of Aggressive (non-Burkitt) B-Cell Lymphoma in a Real Life Cohort

Blood (2019) 134 (Supplement_1): 4122.

https://doi.org/10.1182/blood-2019-123259

Published: 2019

Journal Articles

Lenalidomide Plus Bortezomib and Dexamethasone (RVD) Followed by Lenalidomide Plus Dexamethasone As Salvage Treatment for Myeloma Patients in First Relapse After Autologous Stem Cell Transplantation. Single Institution Experience

Karim Belhadj, MD, Kamel Amraoui, MD, Violaine Safar, MD, Isabelle Gaillard, MD, Taoufik El Gnaoui, MD, Jehan Dupuis, MD, Alain Luciani, MD, PhD, Valérie Molinier-Frenkel, MD, Alain Rahmouni, MD, PhD, Corinne Haioun

Blood (2011) 118 (21): 5143.

https://doi.org/10.1182/blood.V118.21.5143.5143

Published: 2011

Journal Articles

Prognostic Value of Early 18fluorodeoxyglucose PET Scan in Patients with Diffuse Large B Cell Lymphoma Treated with Rituximab Plus CHOP or High-Dose CHOP.

Jehan Dupuis, Emmanuel Itti, Christophe Fruchart, Stéphane Bardet, Alain Rahmouni, Jean-Pierre Vilque, Chieh Lin, Karim Belhadj, Taoufik El Gnaoui, Frédérique Kuhnowski, Michel Meignan, Corinne Haioun

Blood (2008) 112 (11): 2006.

https://doi.org/10.1182/blood.V112.11.2006.2006

Published: 2008

Journal Articles

Cerebrospinal Fluid Immunophenotyping in B-Cell Lymphomas: A Single Centre Experience on 99 Samples.

Anne Plonquet, MD, PhD, Jehan Dupuis, MD, Christo Christov, MD, Christiane Copie-Bergman, MD, PhD, Karim Belhadj, MD, Taoufik El Gnaoui, MD, Isabelle Gaillard, MD, Corinne Haioun, MD

Blood (2007) 110 (11): 2629.

https://doi.org/10.1182/blood.V110.11.2629.2629

Published: 2007

Journal Articles

Response Assessment after an Inductive CHOP or CHOP-Like Regimen with or without Rituximab in 103 Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Integrating 18 Fluorodeoxyglucose Positron Emission Tomography (PET) to the International Workshop Criteria (IWC).

Jehan Dupuis, MD, Emmanuel Itti, MD,PhD, Alain Rahmouni, MD,PhD, Jean-Didier Rain, MD,PhD, Christian Gisselbrecht, MD,PhD, Karim Belhadj, MD, Taoufik El Gnaoui, MD, Isabelle Gaillard, MD, Chieh Lin, MD, Nicolas Mounier, MD,PhD, Philippe Gaulard, MD,PhD, Michel Meignan, MD,PhD, Felix Reyes, MD,PhD, Corinne Haioun, MD

Blood (2006) 108 (11): 2735.

https://doi.org/10.1182/blood.V108.11.2735.2735

Published: 2006

Journal Articles

Rituximab in Combination with CHOP Regimen in Angioimmunoblastic T-Cell Lymphoma (AITL). Preliminary Results in 9 Patients Treated in a Single Institution.

Bertrand Joly, Valerie Frenkel, Philippe Gaulard, Karim Belhadj, Taoufik El Gnaoui, Jehan Dupuis, Marine Divine, Alain Rahmouni, Christiane Copie Bergman, Marie Helene Delfau-Larue, Felix Reyes, Corinne Haioun

Blood (2005) 106 (11): 2686.

https://doi.org/10.1182/blood.V106.11.2686.2686

Published: 2005

Journal Articles

Benefit of the Adjunction of Rituximab in Salvage Regimen before Autologous Stem-Cell Transplantation (ASCT) in Follicular Lymphoma at Relapse. A Single Institution Study.

Karim Belhadj, MD, Yosr Hicheri, MD, Cécile Pautas, MD, Taoufik El Gnaoui, MD, François Hémery, MD, Christiane Copie-Bergman, MD, Jean-Louis Beaumont, MD, Marie-Hélène Delfau-Larue, MD, Jehan Dupuis, MD, Isabelle Gaillard, MD, Marine Diviné, MD, Félix Reyes, MD, Corinne Haioun, MD

Blood (2005) 106 (11): 2075.

https://doi.org/10.1182/blood.V106.11.2075.2075

Published: 2005

Journal Articles

Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX): A Promising Regimen for Refractory/Relapsed B-Cell Lymphoma.

Taoufik El Gnaoui, Jehan Dupuis, Bertrand Joly, Karim Belhadj, Alain Rahmouni, Christiane Copie-Bergman, Antoine Allain, Isabelle Tabah-Fish, Felix Reyes, Corinne Haioun

Blood (2004) 104 (11): 2483.

https://doi.org/10.1182/blood.V104.11.2483.2483

Published: 2004

Journal Articles

Delayed Severe Neutropenia after Rituximab Therapy in 18 among 293 Patients with B-Cell Malignancies Treated in a Single Institution. an Adverse Event of Unknown Mechanism.

Karim Belhadj, Taoufik El Gnaoui, Kamal Doghmi, Bertrand Joly, Ketty Lee, Anne Plonquet, Hélène Jouault, Karine Gourlain, Marie-Hélène Delfau-Larue, Chantal André, Felix Reyes, Corinne Haioun

Blood (2004) 104 (11): 1326.

https://doi.org/10.1182/blood.V104.11.1326.1326

Published: 2004

NARROW

Integrative Study of a High-Grade B-Cell Lymphoma Cohort of 45 Patients: A Single Institution Real Life Study

Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. a Real Life Study in Patients Ineligible for Autologous Transplantation

Clinical, Immunophenotypic and Genetic Characteristics of Aggressive (non-Burkitt) B-Cell Lymphoma in a Real Life Cohort

Lenalidomide Plus Bortezomib and Dexamethasone (RVD) Followed by Lenalidomide Plus Dexamethasone As Salvage Treatment for Myeloma Patients in First Relapse After Autologous Stem Cell Transplantation. Single Institution Experience

Prognostic Value of Early 18fluorodeoxyglucose PET Scan in Patients with Diffuse Large B Cell Lymphoma Treated with Rituximab Plus CHOP or High-Dose CHOP.

Cerebrospinal Fluid Immunophenotyping in B-Cell Lymphomas: A Single Centre Experience on 99 Samples.

Response Assessment after an Inductive CHOP or CHOP-Like Regimen with or without Rituximab in 103 Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Integrating 18 Fluorodeoxyglucose Positron Emission Tomography (PET) to the International Workshop Criteria (IWC).

Rituximab in Combination with CHOP Regimen in Angioimmunoblastic T-Cell Lymphoma (AITL). Preliminary Results in 9 Patients Treated in a Single Institution.

Benefit of the Adjunction of Rituximab in Salvage Regimen before Autologous Stem-Cell Transplantation (ASCT) in Follicular Lymphoma at Relapse. A Single Institution Study.

Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX): A Promising Regimen for Refractory/Relapsed B-Cell Lymphoma.

Delayed Severe Neutropenia after Rituximab Therapy in 18 among 293 Patients with B-Cell Malignancies Treated in a Single Institution. an Adverse Event of Unknown Mechanism.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only